Levetiracetam is not cost effective at June 2011 unit costs. Offerlevetiracetam, oxcarbazepine or sodium valproate (provided the acquisitioncost of levetiracetam falls to at least 50% of June 2011 value documented inthe National Health Service Drug Tariff for England and Wales) if carbamazepine and lamotrigine are unsuitable or not tolerated. Do not do recommendation May 2017
Do not modify the renin angiotensin system antagonist dose if the change in eGFR is less than 25% or the change in serum creatinine is less than 30%. Do not do recommendation May 2017
Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis only if:- the person has a forced vital capacity (FVC) between 50% and 80% predicted and- the manufacturer provides pirfenidone with the discount agreed in the patient access scheme.Treatment with pirfenidone that is recommended as above should be discontinued if there is evidence of disease progression (a decline in per cent predicted FVC of 10% or more within any 12 month period). Do not do recommendation May 2017
Do not offer MRI to women:-of any age at moderate risk of breast cancer- of any age at high risk of breast cancer but with a 30% or lower probability of being a BRCA or TP53 carrier- aged 20 to 29 years who have not had genetic testing but have a greater than 30% probability of being a BRCA carrier- aged 20 to 29 years with a known BRCA1 or BRCA2 mutation- aged 50 to 69 years who have not had genetic testing but have a greater than 30% probability of being a BRCA or a TP53 carrier, unless mammography has shown a dense breast pattern- aged 50 to 69 years with a known BRCA1 or BRCA2 mutation, unless mammography has shown a dense breast pattern.See also: CG164 Summary of recommendations on surveillance for women with no personal history of breast cancer. Do not do recommendation May 2017
Liverpool Healthy Homes: Delivering sustainable house and housing improvements QP Case Study April 2017
Bariatric surgery for non-alcoholic steatohepatitis in obese patients Cochrane Topic April 2017 Very High
Mechanical bowel preparation for elective colorectal surgery Cochrane Topic April 2017 Very Low
Calcium antagonists for aneurysmal subarachnoid haemorrhage Cochrane Topic April 2017 Very Low
Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children Cochrane Topic April 2017 Very Low
High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer Cochrane Topic February 2017 Exclude